Walnut Creek, CA April 17, 2017 – A new proposal by the U.S. Preventive Services Task Force is relaxing its controversial opposition to prostate-specific antigen (PSA) testing for men ages 55 to 69. The revised guidelines come five years after the task force surprised patients and physicians by recommending against the routine use of this commonly used blood test.
According to recent research, the drop in PSA screenings has resulted in a spike in advanced/metastatic prostate cancer, supporting the principle that early detection and early treatment are important. If prostate cancer is detected early while the cancer is still confined to the prostate and treated effectively, there is a higher chance of recovery.
If prostate cancer is not detected early, it can spread outside the prostate and become incurable. The proposal is pending input from the public.